Nonsteroidal antlinflammatory drug use and breast cancer risk: Subgroup findings
Nonsteroidal antlinflammatory drug use and breast cancer risk: Subgroup findings
复制标题
DOI：
10.1093/aje/kwm216
复制
发表时间：
2007-09-15
影响因子：
5
通讯作者：
Theis, Beth
中科院分区：
文献类型：
--
作者：
Kirsh, Victoria A.;Kreiger, Nancy;Theis, Beth
非甾体类抗炎药（NSAID）可能在乳腺癌预防中发挥作用;然而，乳腺癌亚型和生活方式/宿主因素可能会影响其影响。1996-1998年期间，作者在加拿大通过雌激素受体（ER）和孕激素受体（PR）状态、吸烟暴露和关节炎病史，研究了定期使用NSAID（定义为每日使用至少2个月）与乳腺癌风险之间的关系。乳腺癌病例（n = 3，125，包括1，600 ER+PR+和591 ER-PR-）和年龄匹配的随机对照样本（n = 3，062）完成了一般风险因素问卷，包括处方和非处方NSAID使用的详细问题。使用NSAID与乳腺癌风险降低相关（比值比= 0.76，95%置信区间：0.66，0.88）。ER+PR+（比值比= 0.71，95%置信区间：0.60，0.84）和ER-PR-癌症（比值比= 0.80，95%置信区间：0.62，1.03）之间的相关性无显著差异（p（异质性）= 0.66）。在有关节炎和无关节炎的女性中，以及在吸烟人群中，NSAID的负相关程度相似（风险估计值范围为0.74至0.84）。乳腺癌风险倾向于随着NSAID使用时间的增加而降低，并且通常在使用>= 7年时最低，并且乙酰水杨酸和非乙酰水杨酸的使用都与风险降低相关。
Nonsteroidal antiinflammatory drugs (NSAIDs) may play a role in breast cancer prevention; however, breast cancer subtypes and lifestyle/host factors may influence their impact. During 1996-1998 in Canada, the authors examined the association between regular NSAID use (defined as daily use for at least 2 months) and breast cancer risk by estrogen receptor (ER) and progesterone receptor (PR) status, cigarette smoking exposure, and history of arthritis. Breast cancer cases (n = 3,125, including 1,600 ER+PR+ and 591 ER-PR-) and an age-matched, random sample of controls (n = 3,062) completed a general risk factor questionnaire, including detailed questions on prescription and nonprescription NSAID use. NSAID use was associated with reduced risk of breast cancer (odds ratio = 0.76, 95% confidence interval: 0.66, 0.88). The association was not significantly different for ER+PR+ (odds ratio = 0.71, 95% confidence interval: 0.60, 0.84) and ER-PR- cancers (odds ratio = 0.80, 95% confidence interval: 0.62, 1.03) (p(heterogeneity) = 0.66). The magnitude of the NSAID inverse association was similar for women with and without arthritis and across smoking strata (risk estimates ranged from 0.74 to 0.84). Breast cancer risk tended to decrease with increasing duration of NSAID use and was generally lowest for >= 7 years of use, and both acetylsalicylic acid and non-acetylsalicylic acid use were associated with reduced risks.